Cargando…
Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants
Broadly effective and safe anti-coronavirus agent is existentially needed. Major protease (3CL(pro)) is a highly conserved enzyme of betacoronaviruses. The enzyme plays pivotal role in the virus replication cycle. Thus, it is a good target of a broadly effective anti-Betacoronavirus agent. In this s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223907/ https://www.ncbi.nlm.nih.gov/pubmed/35743031 http://dx.doi.org/10.3390/ijms23126587 |
_version_ | 1784733240141021184 |
---|---|
author | Glab-ampai, Kittirat Kaewchim, Kanasap Saenlom, Thanatsaran Thepsawat, Watayagorn Mahasongkram, Kodchakorn Sookrung, Nitat Chaicumpa, Wanpen Chulanetra, Monrat |
author_facet | Glab-ampai, Kittirat Kaewchim, Kanasap Saenlom, Thanatsaran Thepsawat, Watayagorn Mahasongkram, Kodchakorn Sookrung, Nitat Chaicumpa, Wanpen Chulanetra, Monrat |
author_sort | Glab-ampai, Kittirat |
collection | PubMed |
description | Broadly effective and safe anti-coronavirus agent is existentially needed. Major protease (3CL(pro)) is a highly conserved enzyme of betacoronaviruses. The enzyme plays pivotal role in the virus replication cycle. Thus, it is a good target of a broadly effective anti-Betacoronavirus agent. In this study, human single-chain antibodies (HuscFvs) of the SARS-CoV-2 3CL(pro) were generated using phage display technology. The 3CL(pro)-bound phages were used to infect Escherichia coli host for the production the 3CL(pro)-bound HuscFvs. Computerized simulation was used to guide the selection of the phage infected-E. coli clones that produced HuscFvs with the 3CL(pro) inhibitory potential. HuscFvs of three phage infected-E. coli clones were predicted to form contact interface with residues for 3CL(pro) catalytic activity, substrate binding, and homodimerization. These HuscFvs were linked to a cell-penetrating peptide to make them cell-penetrable, i.e., became superantibodies. The superantibodies blocked the 3CL(pro) activity in vitro, were not toxic to human cells, traversed across membrane of 3CL(pro)-expressing cells to co-localize with the intracellular 3CL(pro) and most of all, they inhibited replication of authentic SARS-CoV-2 Wuhan wild type and α, β, δ, and Omicron variants that were tested. The superantibodies should be investigated further towards clinical application as a safe and broadly effective anti-Betacoronavirus agent. |
format | Online Article Text |
id | pubmed-9223907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92239072022-06-24 Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants Glab-ampai, Kittirat Kaewchim, Kanasap Saenlom, Thanatsaran Thepsawat, Watayagorn Mahasongkram, Kodchakorn Sookrung, Nitat Chaicumpa, Wanpen Chulanetra, Monrat Int J Mol Sci Article Broadly effective and safe anti-coronavirus agent is existentially needed. Major protease (3CL(pro)) is a highly conserved enzyme of betacoronaviruses. The enzyme plays pivotal role in the virus replication cycle. Thus, it is a good target of a broadly effective anti-Betacoronavirus agent. In this study, human single-chain antibodies (HuscFvs) of the SARS-CoV-2 3CL(pro) were generated using phage display technology. The 3CL(pro)-bound phages were used to infect Escherichia coli host for the production the 3CL(pro)-bound HuscFvs. Computerized simulation was used to guide the selection of the phage infected-E. coli clones that produced HuscFvs with the 3CL(pro) inhibitory potential. HuscFvs of three phage infected-E. coli clones were predicted to form contact interface with residues for 3CL(pro) catalytic activity, substrate binding, and homodimerization. These HuscFvs were linked to a cell-penetrating peptide to make them cell-penetrable, i.e., became superantibodies. The superantibodies blocked the 3CL(pro) activity in vitro, were not toxic to human cells, traversed across membrane of 3CL(pro)-expressing cells to co-localize with the intracellular 3CL(pro) and most of all, they inhibited replication of authentic SARS-CoV-2 Wuhan wild type and α, β, δ, and Omicron variants that were tested. The superantibodies should be investigated further towards clinical application as a safe and broadly effective anti-Betacoronavirus agent. MDPI 2022-06-13 /pmc/articles/PMC9223907/ /pubmed/35743031 http://dx.doi.org/10.3390/ijms23126587 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Glab-ampai, Kittirat Kaewchim, Kanasap Saenlom, Thanatsaran Thepsawat, Watayagorn Mahasongkram, Kodchakorn Sookrung, Nitat Chaicumpa, Wanpen Chulanetra, Monrat Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title | Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title_full | Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title_fullStr | Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title_full_unstemmed | Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title_short | Human Superantibodies to 3CL(pro) Inhibit Replication of SARS-CoV-2 across Variants |
title_sort | human superantibodies to 3cl(pro) inhibit replication of sars-cov-2 across variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223907/ https://www.ncbi.nlm.nih.gov/pubmed/35743031 http://dx.doi.org/10.3390/ijms23126587 |
work_keys_str_mv | AT glabampaikittirat humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT kaewchimkanasap humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT saenlomthanatsaran humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT thepsawatwatayagorn humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT mahasongkramkodchakorn humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT sookrungnitat humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT chaicumpawanpen humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants AT chulanetramonrat humansuperantibodiesto3clproinhibitreplicationofsarscov2acrossvariants |